A Phase II Study of Carfilzomib with or without ARRY-520 in Patients with Advanced Multiple Myeloma

Full Title

A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma


Carfilzomib is a drug (called a proteasome inhibitor) that has been approved by the FDA to treat patients with relapsed myeloma. In this study, researchers want to determine if adding an investigational drug called ARRY-520 to carfilzomib treatment is more effective than carfilzomib alone in patients with relapsed or refractory multiple myeloma.

ARRY-520 is a novel drug designed to inhibit the growth of myeloma cells by targeting a protein called the “kinesin spindle protein.” Patients will be randomly assigned to receive carfilzomib alone or carfilzomib plus ARRY-520. Both drugs are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that persists despite at least two prior regimens of therapy that included bortezomib (Velcade) as well as lenalidomide (Revlimid), thalidomide, or pomalidomide.
  • Patient may not have been previously treated with carfilzomib.
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Nikoletta Lendvai at 212-639-3368.